M3047
Mizoribine
≥98% (TLC)
别名:
N′-(β-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C9H13N3O6
化学文摘社编号:
分子量:
259.22
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (TLC)
Quality level:
Quality Level
assay
≥98% (TLC)
storage temp.
2-8°C
SMILES string
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O
InChI
1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
InChI key
HZQDCMWJEBCWBR-UUOKFMHZSA-N
Application
Mizoribine has been used in topical treatment to evaluate its effect on ocular surface damage of dry eye in B6 mice subjected to desiccating stress (DS). It has also been used as an inosine monophosphate dehydrogenase (IMPDH) inhibitor to test its in vivo efficacy.
Biochem/physiol Actions
Mizoribine is an imidazole nucleoside possessing strong immunosuppressive properties. It selectively blocks T-cell proliferation response to mitogenic and allo-antigenic stimulation. Mizoribine blocks the movement of T cells from G to S phase. In addition, it significantly decreases the number of B cells at the S, G, and M phases. Mizoribine inhibits de novo synthesis of nucleotides by inhibition of inosine monophosphate dehydrogenase. The resulting nucleotide depletion inhibits DNA synthesis.(3)
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Tomoya Nishino et al.
Internal medicine (Tokyo, Japan), 51(10), 1239-1243 (2012-06-13)
A 52-year-old woman was diagnosed with Blau syndrome and rheumatoid arthritis and was treated with prednisolone and methotrexate. Joint pain and skin ulcers were poorly controlled; therefore, mizoribine (MZ; 150 mg/day) was administered once daily from March 2011. In early
Napoli, K.L.
J. Inter. Fed. Clin. Chem., 4, 15-15 (1992)
Mikiya Fujieda et al.
Clinical nephrology, 78(1), 40-46 (2012-06-27)
To evaluate the efficacy of single-dose oral mizoribine (MZB) pulse therapy given twice weekly for frequently relapsing steroid-dependent nephrotic syndrome (FR-SDNS). The subjects were 8 patients with FR-SDNS with a median age of 6.9 years old (range 3.1 - 18.0
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| M3047-25MG | 04061833066157 |
| M3047-10MG | 04061833066140 |